These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

982 related articles for article (PubMed ID: 30952620)

  • 1. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
    Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
    EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats.
    Wang D; Berglund AE; Kenchappa RS; MacAulay RJ; Mulé JJ; Etame AB
    Sci Rep; 2017 Aug; 7(1):9350. PubMed ID: 28839258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
    Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
    Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches.
    Shakya S; Gromovsky AD; Hale JS; Knudsen AM; Prager B; Wallace LC; Penalva LOF; Brown HA; Kristensen BW; Rich JN; Lathia JD; Brown JM; Hubert CG
    Acta Neuropathol Commun; 2021 May; 9(1):101. PubMed ID: 34059134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy.
    Xie XP; Laks DR; Sun D; Ganbold M; Wang Z; Pedraza AM; Bale T; Tabar V; Brennan C; Zhou X; Parada LF
    Dev Cell; 2022 Jan; 57(1):32-46.e8. PubMed ID: 35016005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples.
    Mukherjee S
    Sci Rep; 2020 Jul; 10(1):10937. PubMed ID: 32616845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
    Steponaitis G; Tamasauskas A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
    Atkins RJ; Stylli SS; Kurganovs N; Mangiola S; Nowell CJ; Ware TM; Corcoran NM; Brown DV; Kaye AH; Morokoff A; Luwor RB; Hovens CM; Mantamadiotis T
    Exp Cell Res; 2019 Jan; 374(2):353-364. PubMed ID: 30562483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
    Bhawe K; Felty Q; Yoo C; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Roy D
    Mol Neurobiol; 2020 Sep; 57(9):3827-3845. PubMed ID: 32594352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
    Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis.
    Kong Y; Feng ZC; Zhang YL; Liu XF; Ma Y; Zhao ZM; Huang B; Chen AJ; Zhang D; Thorsen F; Wang J; Yang N; Li XG
    Front Immunol; 2020; 11():1281. PubMed ID: 32765489
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
    Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.
    Rimkus TK; Carpenter RL; Sirkisoon S; Zhu D; Pasche BC; Chan MD; Lesser GJ; Tatter SB; Watabe K; Debinski W; Lo HW
    Cancer Res; 2018 May; 78(10):2589-2600. PubMed ID: 29463580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation.
    Yoo KC; Suh Y; An Y; Lee HJ; Jeong YJ; Uddin N; Cui YH; Roh TH; Shim JK; Chang JH; Park JB; Kim MJ; Kim IG; Kang SG; Lee SJ
    Oncogene; 2018 Jun; 37(24):3317-3328. PubMed ID: 29559744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of secretome biomarkers in glioblastoma cancer stem cells: A bioinformatics analysis.
    Jangholi E; Tehran HA; Ghasemi A; Hoseinian M; Firoozi S; Ghodsi SM; Tamaddon M; Bereimipour A; Hadjighassem M
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2080. PubMed ID: 38967113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.